We’re attending SLAS 25

Meet us on January 25-29, San Diego Convention Center San Diego, CA (USA). Don’t miss our poster presentation: Title: Enhancing degrader research with CETSA.Date: January 28thTime: 2:00–3:00 pm Meet o...

We’re attending MSD Technology Symposium

Meet us on September 24-25, Greater Philadelphia Expo Center, Oaks, PA (US). New service Learn more about or latest contribution to our service portfolio; Standard Selectivity Profiling, by attending ...

We’re attending BPS New Therapeutic Modalities 2025 

Pelago Bioscience is attending New Therapeutic Modalities: Transforming Receptor Pharmacology, hosted by the British Pharmacological Society, on April 2–3 in Cambridge, UK. This event will bring toget...

Webinar: Applying CETSA® to Translational Studies – A Sitryx Story 

Bridging the Gap Between In Vitro and In Vivo with CETSA  4 March 2025 17:00 CET | 16:00 GMT | 11:00 EST | 08:00 PST Missed the Webinar? We’ve Got You Covered! Translating early drug discovery in...

Unlocking Proteomics: Pelago Bioscience’s HUPO Award-Winning CETSA® approach

Stockholm, Sweden 12 September 2023 Pelago Bioscience proudly receives the HUPO Science and Technology Award, celebrating our pioneering work in CETSA (Cellular Thermal Shift Assay) and the Pelago tea...

University of Southampton acknowledges Pelago Bioscience’s patent and use of CETSA® process

Pelago Bioscience is excited about University of Southampton researchers, led by Professor Tavassoli, having found our patented CETSA® technology useful in their research into identifying hypoxia-indu...

University of Edinburgh acknowledges Pelago Bioscience’s patent and use of CETSA® process

In connection with the CETSA platform, the University of Edinburgh states: “The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled “Methods ...

The Koehler Lab at MIT acknowledges Pelago Bioscience’s patent and use of CETSA® process

Pelago Bioscience celebrates that the Koehler Lab at the Massachusetts Institution of Technology found CETSA® to be a valuable method for quantifying drug Target Engagement in the lab’s experiments de...

Pelago Bioscience showcases at AACR 2025 

April 25–30, 2025 | Chicago, IL | Booth #1656  Pelago Bioscience is exhibiting at the AACR Annual Meeting 2025, where oncology and drug discovery professionals gather to share the latest scientif...

Pelago Bioscience presents at LRIG Philadelphia Annual Vendor Exhibition

Pelago Bioscience is proud to participate in the LRIG Philadelphia Annual Vendor Exhibition. This event brings together scientists, researchers, and technology leaders to explore the latest innovation...

Pelago Bioscience Featured in Top Ten Most Popular Drug Hunter Resources of 2023

We’re delighted to share that our commitment to advancing Drug Discovery has earned us a spot in the “Top Ten Most Popular Drug Hunter Resources of 2023.” The insightful article, “Drug Target Identifi...

Pelago Bioscience AB signs strategic agreement with Cancer Research Horizons

Pelago Bioscience AB signs a strategic agreement with Cancer Research Horizons to unlock quantitative assessment of cellular target engagement across its pipeline of novel oncology programmes. The com...

New privacy policy

We respect your integrity and ensure that your personal data is processed with the confidentiality and respect that is required. Therefore, We have revised our privacy policy.

New CETSA® Publication

Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications In a recent collaboration between AbbVie Chemical...

Modulation Therapeutics, Inc. and Pelago Bioscience AB enter into a CETSA® technology access program and license agreement

Pelago Bioscience today announced the company has entered into a technology access program and license agreement with Modulation Therapeutics, a pharmaceutical company developing therapeutics for the ...

Meet us at BIO-Europe 2024

November 4-6, Stockholmsmässan | Stockholm – Sweden. Our CEO, Michael Dabrowski along with Regional Sales Manager Marianne Alksnis and Head of Sales Magnus Lejelöv, will be attending the Europe&...